ENTERA BIO LTD. Operating Cash Flow
ENTERA BIO LTD. (ENTX) reported Operating Cash Flow of -$6.55 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-07
- ENTERA BIO LTD. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.46M.
- ENTERA BIO LTD. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.09M.
- ENTERA BIO LTD. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.83M.
- ENTERA BIO LTD. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.50M.
- ENTERA BIO LTD. net cash provided by (used in) operating activities for fiscal 2025 was -$7.37M.
- ENTERA BIO LTD. net cash provided by (used in) operating activities for fiscal 2024 was -$6.82M.
- ENTERA BIO LTD. net cash provided by (used in) operating activities for fiscal 2023 was -$7.31M.
- ENTERA BIO LTD. net cash provided by (used in) operating activities for fiscal 2022 was -$12.50M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$6.55M 10-Q · filed 2026-08-07 | -$8.39M derived: sum of 3 quarters · filed 2026-08-07 | -$10.89M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$3.09M 10-Q · filed 2026-05-08 | -$4.92M derived: sum of 2 quarters · filed 2026-05-08 | -$7.42M derived: sum of 3 quarters · filed 2026-05-08 | -$9.06M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$4.33M derived: sum of 2 quarters · filed 2026-03-27 | -$5.97M derived: sum of 3 quarters · filed 2026-08-07 | -$7.37M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$4.13M derived: sum of 2 quarters · filed 2026-08-07 | -$5.54M 10-Q · filed 2025-11-14 | -$7.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$3.04M 10-Q · filed 2026-08-07 | -$4.50M derived: sum of 3 quarters · filed 2026-08-07 | -$6.66M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$1.40M 10-Q · filed 2026-05-08 | -$2.87M derived: sum of 2 quarters · filed 2026-05-08 | -$5.03M derived: sum of 3 quarters · filed 2026-05-08 | -$6.36M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$3.62M derived: sum of 2 quarters · filed 2026-03-27 | -$4.96M derived: sum of 3 quarters · filed 2026-03-27 | -$6.82M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$3.49M derived: sum of 2 quarters · filed 2025-11-14 | -$5.35M 10-Q · filed 2025-11-14 | -$7.97M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$3.20M 10-Q · filed 2025-08-08 | -$5.81M derived: sum of 3 quarters · filed 2025-08-08 | -$7.34M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$1.86M 10-Q · filed 2025-05-09 | -$4.48M derived: sum of 2 quarters · filed 2025-05-09 | -$6.00M derived: sum of 3 quarters · filed 2025-05-09 | -$7.56M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$4.14M derived: sum of 2 quarters · filed 2025-03-28 | -$5.70M derived: sum of 3 quarters · filed 2025-03-28 | -$7.31M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$3.08M derived: sum of 2 quarters · filed 2024-11-08 | -$4.69M 10-Q · filed 2024-11-08 | -$6.70M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$3.17M 10-Q · filed 2024-08-09 | -$5.18M derived: sum of 3 quarters · filed 2024-08-09 | -$8.05M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$1.61M 10-Q · filed 2024-05-10 | -$3.62M derived: sum of 2 quarters · filed 2024-05-10 | -$6.49M derived: sum of 3 quarters · filed 2024-05-10 | -$9.32M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$4.88M derived: sum of 2 quarters · filed 2024-03-08 | -$7.71M derived: sum of 3 quarters · filed 2024-03-08 | -$12.50M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$2.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$5.70M derived: sum of 2 quarters · filed 2023-11-14 | -$10.49M 10-Q · filed 2023-11-14 | -$13.00M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$2.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$7.62M 10-Q · filed 2023-08-11 | -$10.13M derived: sum of 3 quarters · filed 2023-08-11 | -$12.24M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$4.79M 10-Q · filed 2023-05-05 | -$7.30M derived: sum of 2 quarters · filed 2023-05-05 | -$9.41M derived: sum of 3 quarters · filed 2023-05-05 | -$11.53M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | -$2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$4.62M derived: sum of 2 quarters · filed 2023-03-31 | -$6.74M derived: sum of 3 quarters · filed 2023-03-31 | -$9.06M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$4.23M derived: sum of 2 quarters · filed 2022-11-10 | -$6.55M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$2.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$4.44M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$2.32M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$10.56M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |